HIV/AIDS-Related Neuropathy – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of HIV/AIDS-related neuropathy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of HIV/AIDS-related neuropathy for each country, as well as annualized case counts projected to the national population. The latest review of literature did not produce new sources; therefore, we used the sources from the previous update.

Clarivate Epidemiology’s HIV/AIDS-related neuropathy forecast will answer the following questions:

  • Of all people with HIV/AIDS-related neuropathy, how many in each of the major mature pharmaceutical market have been formally diagnosed?
  • Of all people diagnosed with HIV/AIDS-related neuropathy, how many in each of the major mature pharmaceutical market are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HIV/AIDS-related neuropathy over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following HIV/AIDS-related neuropathy subpopulations:

  • Total prevalent cases of HIV/AIDS-related neuropathy.
  • Diagnosed prevalent cases of HIV/AIDS-related neuropathy.
  • Drug-treated prevalent cases of HIV/AIDS-related neuropathy.

Note: Coverage may vary by country.

Table of contents


launch Related Market Assessment Reports